Upadacitinib, DUPILUMAB, Upadacitinib, Upadacitinib, Upadacitinib, Upadacitinib, DUPILUMAB
M17-380
Phase 3 small_molecule active
Quick answer
Upadacitinib, DUPILUMAB, Upadacitinib, Upadacitinib, Upadacitinib, Upadacitinib, DUPILUMAB for Dermatitis atopic is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Dermatitis atopic
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active